{"id":"placebo-ellipta-device","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The ELLIPTA device is an inhalation delivery platform manufactured by GlaxoSmithKline. When used as a placebo, it delivers no active drug substance, serving as a comparator in randomized controlled trials to assess the efficacy of active medications delivered via the same device platform.","oneSentence":"A placebo device with no active pharmaceutical ingredient, used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:50.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control/comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT04813354","phase":"PHASE4","title":"A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-14","conditions":"Asthma","enrollment":114},{"nctId":"NCT02522299","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT04536675","phase":"PHASE3","title":"Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-04-01","conditions":"Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer","enrollment":204},{"nctId":"NCT03645434","phase":"PHASE2","title":"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-10-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":73},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT02483975","phase":"PHASE3","title":"Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-09","conditions":"Asthma","enrollment":111},{"nctId":"NCT02982187","phase":"PHASE4","title":"A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":160},{"nctId":"NCT03175926","phase":"NA","title":"Description of the Ability to Learn How to Handle Inhaler Devices in Asthma","status":"WITHDRAWN","sponsor":"University Hospital, Bordeaux","startDate":"2017-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT02786927","phase":"PHASE4","title":"Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":214},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT02596009","phase":"PHASE4","title":"Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-16","conditions":"Pulmonary Disease, Chronic Obstructive (COPD)","enrollment":97},{"nctId":"NCT02551224","phase":"NA","title":"Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Pulmonary Disease, Chronic Obstructive (COPD)","enrollment":100},{"nctId":"NCT02184624","phase":"PHASE4","title":"Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":569},{"nctId":"NCT02195284","phase":"PHASE4","title":"To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11","conditions":"Asthma","enrollment":162},{"nctId":"NCT01868009","phase":"PHASE3","title":"DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":287}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo ELLIPTA device","genericName":"Placebo ELLIPTA device","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo device with no active pharmaceutical ingredient, used as a control in clinical trials. Used for Clinical trial control/comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}